Table 3.
Number of subjects categorized according to time spent in remission divided by subject-specific follow-up duration, for each of the remission criteria tested
| All subjects in BRASS with ≥2 years of follow-up | |||||
|---|---|---|---|---|---|
| Time in remission (%) |
DAS28-CRP < 2.6 N = 871a |
DAS28-CRP < 2.3 N = 871a |
SDAI N = 871a |
CDAI N = 871a |
ACR/EULAR N = 871a |
| 0 | 326 (37%) | 401 (46%) | 599 (69%) | 610 (70%) | 634 (73%) |
| 1-25 | 130 (15%) | 146 (17%) | 94 (11%) | 30 (3%) | 87 (10%) |
| 26-50 | 196 (23%) | 163 (19%) | 108 (12%) | 127 (15%) | 101 (12%) |
| 51-75 | 121 (14%) | 102 (12%) | 52 (6%) | 66 (8%) | 39 (4%) |
| 76-99 | 52 (6%) | 30 (3%) | 10 (1%) | 17 (2%) | 7 (1%) |
| 100 | 46 (5%) | 29 (3%) | 8 (1%) | 21 (2%) | 3 (0.3%) |
| Overall mean time in remission | 31% | 24% | 12% | 15% | 10% |
| Selected population of subjects in BRASS | |||||
| Time in remission (%) |
DAS28-CRP < 2.6 N = 309b |
DAS28-CRP < 2.3 N = 275b |
SDAI N = 168b |
CDAI N = 170b |
ACR/EULAR N = 158b |
| 1-25 | 77 (25%) | 89 (32%) | 58 (35%) | 54 (32%) | 60 (38%) |
| 26-50 | 133 (43%) | 111 (40%) | 62 (37%) | 72 (42%) | 64 (41%) |
| 51-75 | 49 (16%) | 37 (13%) | 30 (18%) | 24 (14%) | 18 (11%) |
| 76-99 | 28 (9%) | 21 (8%) | 6 (4%) | 7 (4%) | 8 (5%) |
| 100 | 22 (7%) | 17 (6%) | 12 (7%) | 13 (8%) | 8 (5%) |
| Overall mean time in remission |
48% | 45% | 44% | 44% | 42% |
aSubjects in BRASS with ≥2 years of follow-up. Maximum number of visits is eight. bSubjects in BRASS with ≥2 years of follow-up, one or more visits in remission, according to the various
definitions; ≥1 year follow-up after first visit in remission and not in remission at entrance into
BRASS. Maximum number of visits is seven (because visit at entrance into BRASS is excluded).